Cardiff Oncology, Inc.
CRDF Healthcare Biotechnology
Cardiff Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $593,000.00, down 13.2% from fiscal 2024. In the quarter to June 2026, revenue fell 14.1%, EPS grew 33.3% and free cash flow fell 41.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CRDF
Cardiff Oncology, Inc. (CRDF) EV/Sales
As of 16 October 2026, Cardiff Oncology, Inc. (CRDF) trades at a EV/Sales of 57.3×. Over the past ten years it has ranged from −214× (May 2022) to 1,593× (November 2020); the current reading is higher than 42% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 221× | 29.48% |
| FY2024 | 171× | — |
| FY2023 | −10.4× | — |
| FY2022 | −102× | — |
| FY2021 | 265× | (60.56%) |
| FY2020 | 672× | 7,492.30% |
| FY2019 | 8.9× | (77.08%) |
| FY2018 | 38.6× | 17.80% |
| FY2017 | 32.8× | (69.15%) |
| FY2016 | 106× | (63.25%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 110× | (12.72%) |
| Mar 2026 | 126× | (42.99%) |
| Dec 2025 | 221× | 40.47% |
| Sep 2025 | 157× | (38.82%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| PDSB PDS Biotechnology Corporation compare | n/m |
| HRTX Heron Therapeutics, Inc. compare | 1.1× |
| PTHS Pelthos Therapeutics Inc. compare | 2.7× |
| NTRB Nutriband Inc. compare | 44.7× |
| CRDF Cardiff Oncology, Inc. | 57.3× |
| PMN Promis Neurosciences compare | 11,382× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)